Amrize Ltd
AMRZNYSEBasic Materials● Active
$52.33
$-1.23(-2.30%)
Market Cap$28.9B
P/E Ratio—
52W High$65.94
52W Low$44.12
Amrize Ltd（AMRZ）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · AMRZ · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $11.81B | $11.70B | $11.68B | $10.73B | $8.13B |
| Cost of Revenue | $8.78B | $8.63B | $8.91B | $8.25B | $6.31B |
| Gross Profit | $3.03B | $3.07B | $2.77B | $2.47B | $1.82B |
| Gross Margin %(computed) | 25.68% | 26.23% | 23.71% | 23.05% | 22.36% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.90B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $1.13B | $0.89B | $0.88B | $0.77B | $0.53B |
| Operating Income | $1.91B | $2.18B | $1.89B | $1.70B | $1.29B |
| Operating Margin %(computed) | 16.13% | 18.60% | 16.17% | 15.84% | 15.84% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.30B | $0.55B | $0.25B | $0.18B |
| Income Before Tax | $1.51B | $1.83B | $1.32B | $1.47B | $1.13B |
| Income Tax Expense | $0.33B | $0.41B | $0.36B | $0.37B | $0.28B |
| Net Income | $1.19B | $1.42B | $0.96B | $1.11B | $0.84B |
| Net Margin %(computed) | 10.03% | 12.12% | 8.19% | 10.33% | 10.34% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.14 | $2.30 | $1.73 | $2.00 | $1.52 |
| Wtd Avg Shares | 0.55B | 0.55B | 0.55B | 0.55B | 0.55B |
| EBITDA | $2.82B | $3.01B | $2.70B | $2.50B | $2.00B |
| EBITDA Margin %(computed) | 23.87% | 25.73% | 23.15% | 23.27% | 24.66% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Amrize Ltd
关于Amrize Ltd（AMRZ）损益表
Amrize Ltd（AMRZ）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，AMRZ实现营收$11.81B，毛利润$3.03B（毛利率25.68%），净利润$1.19B（净利率10.03%）。
常见问题
AMRZ · 4 问Amrize Ltd（AMRZ）2025财年营收为$11.81B，同比up0.9%。
AMRZ revenueAMRZ salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08